http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113072562-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2021-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113072562-B |
| titleOfInvention | A kind of GSK-3β inhibitor and its preparation method and application |
| abstract | The application provides a GSK-3β inhibitor, a preparation method and application thereof, and the structure of the GSK-3β inhibitor is shown in formula SP: Wherein, R 1 is selected from alkyl, cycloalkyl, aryl, and substituted aryl; R 2 and R 3 are each independently selected from H, aryl, and substituted aryl. The compound of formula SP is a new type of GSK-3β inhibitor, has good GSK-3β inhibitory activity, and can inhibit the abnormal phosphorylation of tau protein induced by Aβ in a dose-dependent manner. The compound of formula SP of the present invention can be used as a hit compound for evaluation of anti-Alzheimer's disease activity, and provides a basis for the research and development of new anti-Alzheimer's disease drugs. |
| priorityDate | 2021-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 292.